Catumaxomab was developed by Trion Pharma, based on preliminary work by the Helmholtz Zentrum München.
This software package was developed by scientists of the Institute of Radiation Protection of the Helmholtz Zentrum München, German Research Center for Environmental Health (former GSF - National Research Center for Environmet and Health) with support from the European Commission and University of Siegen, Germany.
The development of EuroPhenome is in collaboration with the Helmholtz Zentrum München, the Wellcome Trust Sanger Institute, and the Clinique de la Souris (France).
München | Hermann von Helmholtz | TSV 1860 München | Hochschule für Musik und Theater München | Technische Universität München | München Donnersbergerbrücke station | Garching bei München | München-Laim station | Helmholtz Zentrum München | Helmholtz | München Rosenheimer Platz station | Munchen | Zentrum | Schauspiel München | Neue Künstlervereinigung München | München Solln station | München-Pasing station | München Marienplatz station | Helmholtz-Zentrum Berlin | Helmholtz resonance | Helmholtz reciprocity | Helmholtz decomposition | Helmholtz Centre Potsdam GFZ German Research Centre for Geosciences | GSI Helmholtz Centre for Heavy Ion Research | Botanischer Garten München-Nymphenburg |